Alzheimer’s progress slowed by plaque-busting drug
New Scientist - 25-Mar-2015In a small trial, the drug slowed the progression of the disease and reduced deposits of amyloid ...
Join the club for FREE to access the whole archive and other member benefits.
EVP, R&D and Chief Medical Officer at Biogen.
Alfred W. Sandrock, Jr., M.D., Ph.D., is Executive Vice President, Research & Development at Biogen and has served on the Executive Committee since 2015. He has served as the head of Research & Development since October 2019 and was our Chief Medical Officer from 2012 until January 2020. Since joining the company in 1998, he has held several senior executive positions, including Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. Dr. Sandrock received his B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital.
Visit website: https://www.biogen.com/en_us/leadership/leadership-detail.sandrock_alfred.html
See also: Biogen - Company specialized in the discovery, development, and delivery of therapies for the treatment of neurological diseases
Details last updated 24-Jul-2020
In a small trial, the drug slowed the progression of the disease and reduced deposits of amyloid ...